LOXL2 Antibody (YA9979)
(Synonyms: LOR2; LOX L2; LOXL2; Lysyl oxidase homolog 2; Lysyl oxidase like 2; WS9 14)Based on 1 Customer Validation
LOXL2 Antibody (YA9979) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to LOXL2.
-
Host:
Rabbit
-
Isotype:
IgG
-
Application:
WB, IHC-P, ICC/IF, FC
-
Reactivity :
Human, Mouse, Rat
-
Formulation:
Supplied in 1*TBS (pH7.4), 0.05% BSA, 40% Glycerol. Preservative: 0.05% Sodium Azide.
-
Conjugation:
Non-conjugated
Applications
| Application |
WB
WB: Western Blot
|
ICC/IF
ICC/IF: Immunocytochemistry/
Immunofluorescence |
IHC-P
IHC-P: Immunohistochemistry-Paraffin
|
FC
FC: Flow Cytometry
|
|---|---|---|---|---|
| Dilution Ratio | 1:500-1:2,000 | 1:50-1:200 | 1:50-1:100 | 1:50-1:100 |
Product Details
LOXL2 Antibody (YA9979) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to LOXL2.
-
Host Rabbit
-
Clonality Recombinant,Monoclonal
-
Species ReactivityHuman, Mouse, Rat
-
Observed Molecular WeightObserved band size: 53/106 kDaNote: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.
-
Calculated Molecular Weight Predicted band size: 87 kDa
Entrez Gene: 4017 Human ; 94352 Mouse ; 290350 Rat
SwissProt: Q9Y4K0 Human ; P58022 Mouse ; B5DF27 Rat
OMIM: 606663 Human
Synthetic peptide within C-terminal human LOXL2.
Endogenous
Affinity Chromatography
Non-conjugated
Unmodified
IgG
Product Properties
-
Appearance
Solution
-
Formulation
Supplied in 1*TBS (pH7.4), 0.05% BSA, 40% Glycerol. Preservative: 0.05% Sodium Azide.
-
Concentration
Batch-dependent, Please check the COA for the concentration of each lot. Check Lot Concentration
-
Storage & Stability
Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.
-
Shipping
Shipping with blue ice.
Verification Images
-
Western blot analysis was performed on protein extracts (25 μg) from HeLa (lane 2), MCF-7 (lane 3), U87 (lane 4), Rat brain (lane 5), and Mouse brain (lane 6) using LOXL2 antibody. Proteins were transferred onto a 0.45 μm PVDF membrane using the Trans-Blot® Turbo™ system for 13 min. The membrane was then blocked with 5% nonfat milk in TBST (HY-K1025) for 1 h at room temperature. The primary antibody (1:1000) and loading control antibody GAPDH Antibody (HRP) (HY-P80954A) (1:5000) were diluted in 5% nonfat milk in TBST and incubated with the membrane overnight at 4°C. After washing, the membrane of primary antibody was incubated with HRP-conjugated goat anti-rabbit/mouse IgG secondary antibody (HY-P8001/HY-P8004) (1:5000) diluted in 5% nonfat milk in TBST for 1 h at room temperature. Protein bands were visualized using an Ultra High Sensitivity ECL detection kit (HY-K1005).
Background
-
Function
LOXL2 mediates the post-translational oxidative deamination of lysine residues on target proteins leading to the formation of deaminated lysine (allysine). Acts as a transcription corepressor and specifically mediates deamination of trimethylated 'Lys-4' of histone H3 (H3K4me3), a specific tag for epigenetic transcriptional activation. Shows no activity against histone H3 when it is trimethylated on 'Lys-9' (H3K9me3) or 'Lys-27' (H3K27me3) or when 'Lys-4' is monomethylated (H3K4me1) or dimethylated (H3K4me2). Also mediates deamination of methylated TAF10, a member of the transcription factor IID (TFIID) complex, which induces release of TAF10 from promoters, leading to inhibition of TFIID-dependent transcription. LOXL2-mediated deamination of TAF10 results in transcriptional repression of genes required for embryonic stem cell pluripotency including POU5F1/OCT4, NANOG, KLF4 and SOX2. Involved in epithelial to mesenchymal transition (EMT) via interaction with SNAI1 and participates in repression of E-cadherin CDH1, probably by mediating deamination of histone H3. During EMT, involved with SNAI1 in negatively regulating pericentromeric heterochromatin transcription. SNAI1 recruits LOXL2 to pericentromeric regions to oxidize histone H3 and repress transcription which leads to release of heterochromatin component CBX5/HP1A, enabling chromatin reorganization and acquisition of mesenchymal traits. Interacts with the endoplasmic reticulum protein HSPA5 which activates the IRE1-XBP1 pathway of the unfolded protein response, leading to expression of several transcription factors involved in EMT and subsequent EMT induction. Involved in E-cadherin repression following hypoxia, a hallmark of EMT believed to amplify tumor aggressiveness, suggesting that it may play a role in tumor progression. When secreted into the extracellular matrix, promotes cross-linking of extracellular matrix proteins by mediating oxidative deamination of peptidyl lysine residues in precursors to fibrous collagen and elastin. Acts as a regulator of sprouting angiogenesis, probably via collagen IV scaffolding. Acts as a regulator of chondrocyte differentiation, probably by regulating expression of factors that control chondrocyte differentiation[1][2][3][4][5][6][7][8][9].
-
Subcellular Localization
Secreted, extracellular space, extracellular matrix, basement membrane; Nucleus; Chromosome; Endoplasmic reticulum
-
Expression
Tissue_specificity:Expressed in many tissues (PubMed:10212285) . Highest expression in reproductive tissues, placenta, uterus and prostate (PubMed:10212285) . In esophageal epithelium, expressed in the basal, prickle and granular cell layers (PubMed:22204712) . Up-regulated in a number of cancers cells and tissues
Induction:Strongly induced in hypoxia. Direct transcriptional target of HIF1A -
Subunit
Component of some chromatin repressor complex. Interacts with SNAI1 (PubMed:16096638). Interacts with TAF10 (PubMed:25959397). Interacts with HSPA5 (PubMed:28332555). Interacts with EFEMP2 (PubMed:27339457)
-
SwissProt ID
-
Synonyms
LOR2; LOX L2; LOXL2; Lysyl oxidase homolog 2; Lysyl oxidase like 2; WS9 14
-
Research Field
Signal Transduction
Documentation